SuteNamo IP 25 mg
Sunitinib Malate
Sutenamo 25mg is used to treat liver, kidney, and thyroid cancers. It works by blocking tumour growth and cutting off blood supply to cancer cells.
- Strengths 25mg
- Form Capsule
- Packaging Size 28 Capsules
- Packaging Type Box
- Manufacturer Adley Formulations pvt ltd
Description of SuteNamo IP 25 mg
Sutenamo 25mg belongs to a class of anti-cancer drugs called tyrosine kinase inhibitors. It is primarily used for the treatment of kidney cancer (renal cell carcinoma), liver cancer, and certain types of thyroid cancer. The active ingredient, Sunitinib Malate, works by blocking specific proteins that promote cancer cell growth and cutting off the blood supply that tumours need to grow. Sutenamo is typically taken orally once a day and should be used under strict medical supervision. Regular blood tests and monitoring are essential to ensure the treatment’s effectiveness and manage potential side effects.
Ingredients of SuteNamo IP 25 mg
- Lenalidomide – 25mg (Active Ingredient)
- Capsule base and excipients (Inactive Ingredients)
Usage of SuteNamo IP 25 mg
- Taken orally, with or without food.
- Dosage is based on the condition, patient response, and other treatments.
- Swallow whole—do not crush or chew.
- Usually taken in cycles (e.g., daily for 21 days, followed by rest).
- Always follow your doctor’s instructions exactly.
Precautions for SuteNamo IP 25 mg
- Strictly avoid during pregnancy—can cause birth defects.
- Inform your doctor about kidney issues or blood disorders.
- May cause fatigue, nausea, or low blood counts—regular monitoring required.
- Use effective contraception during and after treatment.
- Do not donate blood or sperm while on this medication.
More like this
Find related medicines from trusted suppliers. Explore similar products to ensure you get the right medication for your needs.
